Latanoprost is an isopropyl ester prodrug used to treat increased intraocular pressure. It was initially approved by the FDA in 1998.
- Mechanism
- Curator reviewed · 4 references
Elevated intraocular pressure leads to an increased risk of glaucomatous visual field loss. The higher the intraocular pressure, the higher the risk of damage to the optic nerve and loss of visual field. Latanoprost selectively stimulates the prostaglandin F2 alpha receptor and this results in a decreased intraocular pressure (IOP) via the increased outflow of aqueous humor, which is often implicated in cases of elevated intraocular pressure. Possible specific mechanisms of the abovementioned increased aqueous outflow are the remodeling of the extracellular matrix and regulation of matrix metalloproteinases. These actions result in higher tissue permeability related to humor outflow pathways, which likely change outflow resistance and/or outflow rates.
- Primary indication
- Latanoprost is indicated for the reduction of elevated intraocular pressure in patients who have been diagnosed with open-angle glaucoma or ocular hypertension.Curator reviewed · 6 structured indications
- Formula / weight
- C26H40O5 · 432.5928 g/mol (avg)
- First approval
- Canada, 2011 · United States, 1995 · European Union, 2021
- Also known as
- 5-HEPTENOIC ACID, 7-(3,5-DIHYDROXY-2-(3-HYDROXY-5-PHENYLPENTYL)CYCLOPENTYL)-1-METHYLETHYL ESTER, (1R-(1.ALPHA.(Z),2.BETA.(R*),3.ALPHA.,5.ALPHA.))- · Isopropyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoate
- Code names
- PHXA-41 · T-2345 · XA-41
- Brand names
Resolves to
GGXICVAJURFBLW-CEYXHVGTSA-NSMILESCC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Latanoprost, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account